StartUp Health’s Post

Cognito Therapeutics is taking a unique approach in tackling Alzheimer's disease. The company has developed a neuromodulation headset that delivers flashing gamma-frequency light and sounds to stimulate gamma oscillations in the brain. The therapy aims to change the pathology of proteins associated with neurodegenerative diseases. The phase 2 clinical trial data published last month showed that patients with Alzheimer's using the headset for an hour each day for 6 months saw their total cerebral white matter volume increase, while the placebo group saw their volume decrease. Additionally, patients using the headset experienced a slower loss in myelin content. Cognito's innovative approach is paving the way for a novel breakthrough in Alzheimer's treatment. The company is currently enrolling participants for a phase 3 clinical trial. #AlzheimersDisease #HealthTech #BrainHealth #MedicalResearch #Dementia #AlzheimersResearch #LightTherapy #SoundTherapy

📢 Hot off the press in Wiley #neuroprotection: Neuroprotective effects of repetitive transcranial magnetic stimulation on #Alzheimer's disease: Undetermined therapeutic protocols and mechanisms Key points - Stimulus frequency, pattern of stimulation, stimulus intensity, and the configuration of the stimulus coil are important factors in the repetitive transcranial magnetic stimulation (#rTMS) treatment of Alzheimer's disease (AD). - Multisite high-frequency (HF)-rTMS and HF-r#TMS applied over the left dorsolateral prefrontal cortex, precuneus, or cerebellum are promising protocols in AD therapy. - Novel intermittent transcranial magnetic stimulation treatments for #AD are cost-effective and show long-lasting effects. - Interacting mechanisms result in rTMS's improvement of AD cognition, including modulation of brain network, as well as cellular and molecular reactions. - This review provides theoretical and practical evidence for the future clinical application and scientific research of rTMS in AD. https://lnkd.in/dc8PvJ-M

Hot off the press in #neuroprotection: Neuroprotective effects of repetitive transcranial magnetic stimulation on #Alzheimer's disease: Undetermined therapeutic protocols and mechanisms #rTMS #TMS https://lnkd.in/dc8PvJ-M Key points Stimulus frequency, pattern of stimulation, stimulus intensity, and the configuration of the stimulus coil are important factors in the repetitive transcranial magnetic stimulation (rTMS) treatment of Alzheimer's disease (AD). - Multisite high-frequency (HF)-rTMS and HF-rTMS applied over the left dorsolateral prefrontal cortex, precuneus, or cerebellum are promising protocols in AD therapy. - Novel intermittent transcranial magnetic stimulation treatments for AD are cost-effective and show long-lasting effects. - Interacting mechanisms result in rTMS's improvement of AD cognition, including modulation of brain network, as well as cellular and molecular reactions. - This review provides theoretical and practical evidence for the future clinical application and scientific research of rTMS in AD.

No current treatments can reverse the effects of neurological diseases. Cell therapies could promote brain repair - if researchers can get them to stick. This material, developed by researchers across 10 years and three Australian universities, promotes cell survival and supports the transplant. Read more below. #StemCellResearch #StemCellTransplant #StemCellTherapy #CellTherapy

Predominant right temporal lobe atrophy: Clinical, neuropsychological and structural differences based on amyloid status Patients with predominant right temporal atrophy showed clinical, neuropsychological and radiological differences, depending on the status of amyloid biomarkers. #rightvariant #AD #FTD #amyloid

Over the past decade, we have consistently found disturbed cerebral microcirculation in Alzheimer's disease (AD), prodromal AD, and now in preclinical AD. The evidence for involvement of small vessels and neurovascular coupling in the pathophysiology of AD is overwhelming. This gives hope for new therapies targeting the vascular system in the treatment of AD. https://lnkd.in/eRWM53Hb

Throughout the #PD continuum, many pathological changes manifest. Employing a translational approach, Gesine Paul particularly focuses on the #neurovascular unit, exploring its changes during disease progression and as a drug target for brain repair. #ParkinsonsAwarenessMonth Use link below to learn more about her research, which also involves clinical implementation of stem cells and growth factors to treat Parkinson's. https://lnkd.in/d-ubN5kH

https://lnkd.in/d7rN-Gct Alzheimer's disease (AD) is a diffused neurodegenerative disorder affecting people in advanced age causing loss of memory and dementia. Nowadays, diagnosis and treatment of AD are still challenging due to the lack of diagnostic systems that allow for an early and reliable diagnosis and therapy monitoring. Moreover, conventional strategies for AD diagnosis are based on brain imaging techniques that are invasive and expensive for early and massive screening. Phage display approach, using engineered phage probe for direct amyloid-β (Aβ)-autoantibodies detection, overcome these limitations leading to the possibility of safe and low-cost screening. Moreover, the combination with silicon technology further improves the easiness of diagnosis due to the portability of devices and the integration of sensitive transduction signals. In this work, an innovative silicon-based sensing technology is reported detecting Aβ-autoantibodies, specifically Immunoglobulin G (IgG), in human sera by engineered M13-phage probes (ADPP). The strategy hinges on a bio-surface that is integrated on top of a silicon biosensor. Thanks to phages probes exposing Aβ-mimic peptides, this chip can capture and reveal Aβ-autoantibodies, discriminating between healthy and AD conditions. The surface chemistry is morphologically and chemically characterized and the phage-based biosensor ability to recognise Aβ-autoantibodies is proved by transduction with enzyme-linked anti-M13 antibodies.